Synopsis
Synopsis
0
KDMF
0
VMF
0
Australia
Annual Reports
NA
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 6029 M
2. 6029-m
3. 6029m
4. Buprenex
5. Buprenorphine
6. Buprenorphine Hydrochloride
7. Buprex
8. Hydrochloride, Buprenorphine
9. Prefin
10. Rx 6029 M
11. Rx-6029-m
12. Rx6029m
13. Subutex
14. Temgsic
15. Temgesic
1. Buprenorphine Hydrochloride
2. Ncgc00247733-01
3. Dsstox_cid_28831
4. Dsstox_rid_83100
5. Dsstox_gsid_48905
6. Tox21_112899
7. Cas-53152-21-9
Molecular Weight | 504.1 g/mol |
---|---|
Molecular Formula | C29H42ClNO4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 5 |
Exact Mass | 503.2802365 g/mol |
Monoisotopic Mass | 503.2802365 g/mol |
Topological Polar Surface Area | 62.2 Ų |
Heavy Atom Count | 35 |
Formal Charge | 0 |
Complexity | 869 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 6 |
Undefined Atom Stereocenter Count | 1 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 2 | |
---|---|
Drug Name | Buprenorphine hydrochloride |
Drug Label | Buprenorphine hydrochloride sublingual tablets contains buprenorphine HCl.Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Buprenorphine is a Schedule III narcotic under the Controlled Subst... |
Active Ingredient | Buprenorphine hydrochloride |
Dosage Form | Injectable; Tablet |
Route | Sublingual; Injection |
Strength | eq 2mg base; eq 0.3mg base/ml; eq 8mg base |
Market Status | Prescription |
Company | Hospira; Ethypharm; Luitpold; Eurohlth Intl; Roxane; Barr |
2 of 2 | |
---|---|
Drug Name | Buprenorphine hydrochloride |
Drug Label | Buprenorphine hydrochloride sublingual tablets contains buprenorphine HCl.Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Buprenorphine is a Schedule III narcotic under the Controlled Subst... |
Active Ingredient | Buprenorphine hydrochloride |
Dosage Form | Injectable; Tablet |
Route | Sublingual; Injection |
Strength | eq 2mg base; eq 0.3mg base/ml; eq 8mg base |
Market Status | Prescription |
Company | Hospira; Ethypharm; Luitpold; Eurohlth Intl; Roxane; Barr |
Sixmo is indicated for substitution treatment for opioid dependence in clinically stable adult patients who require no more than 8 mg/day of sublingual buprenorphine, within a framework of medical, social and psychological treatment.
Treatment of opioid dependence
Analgesics, Opioid
Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. (See all compounds classified as Analgesics, Opioid.)
Narcotic Antagonists
Agents inhibiting the effect of narcotics on the central nervous system. (See all compounds classified as Narcotic Antagonists.)
Narcotics
Agents that induce NARCOSIS. Narcotics include agents that cause somnolence or induced sleep (STUPOR); natural or synthetic derivatives of OPIUM or MORPHINE or any substance that has such effects. They are potent inducers of ANALGESIA and OPIOID-RELATED DISORDERS. (See all compounds classified as Narcotics.)
N07BC01
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Complete
Rev. Date : 2019-06-04
Pay. Date : 2016-09-08
DMF Number : 29885
Submission : 2016-08-16
Status : Active
Type : II
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Complete
Rev. Date : 2012-11-23
Pay. Date : 2012-11-23
DMF Number : 23683
Submission : 2010-04-05
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-12-26
Pay. Date : 2012-11-30
DMF Number : 19109
Submission : 2006-01-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7099
Submission : 1987-08-06
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2012-11-30
Pay. Date : 2012-11-13
DMF Number : 16419
Submission : 2003-01-29
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12412
Submission : 1997-03-10
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7684
Submission : 1988-09-16
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-10-26
Pay. Date : 2012-12-03
DMF Number : 21060
Submission : 2007-11-12
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2020-01-14
Pay. Date : 2020-01-09
DMF Number : 22856
Submission : 2009-08-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7923
Submission : 1989-01-23
Status : Inactive
Type : II
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
88
PharmaCompass offers a list of Buprenorphine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Buprenorphine Hydrochloride manufacturer or Buprenorphine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Buprenorphine Hydrochloride manufacturer or Buprenorphine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Buprenorphine Hydrochloride API Price utilized in the formulation of products. Buprenorphine Hydrochloride API Price is not always fixed or binding as the Buprenorphine Hydrochloride Price is obtained through a variety of data sources. The Buprenorphine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Buprenorphine HCl manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Buprenorphine HCl, including repackagers and relabelers. The FDA regulates Buprenorphine HCl manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Buprenorphine HCl API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Buprenorphine HCl manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Buprenorphine HCl supplier is an individual or a company that provides Buprenorphine HCl active pharmaceutical ingredient (API) or Buprenorphine HCl finished formulations upon request. The Buprenorphine HCl suppliers may include Buprenorphine HCl API manufacturers, exporters, distributors and traders.
click here to find a list of Buprenorphine HCl suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Buprenorphine HCl DMF (Drug Master File) is a document detailing the whole manufacturing process of Buprenorphine HCl active pharmaceutical ingredient (API) in detail. Different forms of Buprenorphine HCl DMFs exist exist since differing nations have different regulations, such as Buprenorphine HCl USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Buprenorphine HCl DMF submitted to regulatory agencies in the US is known as a USDMF. Buprenorphine HCl USDMF includes data on Buprenorphine HCl's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Buprenorphine HCl USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Buprenorphine HCl suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Buprenorphine HCl Drug Master File in Japan (Buprenorphine HCl JDMF) empowers Buprenorphine HCl API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Buprenorphine HCl JDMF during the approval evaluation for pharmaceutical products. At the time of Buprenorphine HCl JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Buprenorphine HCl suppliers with JDMF on PharmaCompass.
A Buprenorphine HCl CEP of the European Pharmacopoeia monograph is often referred to as a Buprenorphine HCl Certificate of Suitability (COS). The purpose of a Buprenorphine HCl CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Buprenorphine HCl EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Buprenorphine HCl to their clients by showing that a Buprenorphine HCl CEP has been issued for it. The manufacturer submits a Buprenorphine HCl CEP (COS) as part of the market authorization procedure, and it takes on the role of a Buprenorphine HCl CEP holder for the record. Additionally, the data presented in the Buprenorphine HCl CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Buprenorphine HCl DMF.
A Buprenorphine HCl CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Buprenorphine HCl CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Buprenorphine HCl suppliers with CEP (COS) on PharmaCompass.
A Buprenorphine HCl written confirmation (Buprenorphine HCl WC) is an official document issued by a regulatory agency to a Buprenorphine HCl manufacturer, verifying that the manufacturing facility of a Buprenorphine HCl active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Buprenorphine HCl APIs or Buprenorphine HCl finished pharmaceutical products to another nation, regulatory agencies frequently require a Buprenorphine HCl WC (written confirmation) as part of the regulatory process.
click here to find a list of Buprenorphine HCl suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Buprenorphine HCl as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Buprenorphine HCl API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Buprenorphine HCl as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Buprenorphine HCl and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Buprenorphine HCl NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Buprenorphine HCl suppliers with NDC on PharmaCompass.
Buprenorphine HCl Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Buprenorphine HCl GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Buprenorphine HCl GMP manufacturer or Buprenorphine HCl GMP API supplier for your needs.
A Buprenorphine HCl CoA (Certificate of Analysis) is a formal document that attests to Buprenorphine HCl's compliance with Buprenorphine HCl specifications and serves as a tool for batch-level quality control.
Buprenorphine HCl CoA mostly includes findings from lab analyses of a specific batch. For each Buprenorphine HCl CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Buprenorphine HCl may be tested according to a variety of international standards, such as European Pharmacopoeia (Buprenorphine HCl EP), Buprenorphine HCl JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Buprenorphine HCl USP).